Organic Active Ingredients TRIZ Cases

A phased landiolol regimen sustains heart-rate reduction during treatment while limiting tolerance, overshoot, and venous irritation.

ILDR2 antagonist combinations with PD-L1 blockers, taxanes, or CpG agents address limited checkpoint efficacy through synergistic tumor growth delay.

Formula I dication compounds address the tradeoff between non-depolarizing safety and ultra-short muscle-relaxant action without reversal agents.

Traditional sarcopenia treatments are inadequate; systems biology and drug repositioning identify compounds that raise myogenic markers.

Buffering, tonicity adjustment, and compatible hyaluronic acid support a stable triamcinolone acetonide composition that is easy to inject into the suprachoroidal space.

Acidic-pH binding boosts GluN2B inhibition where NMDARs are activated, addressing weak efficacy and side effects of earlier antagonists.

Intranasal NAC crosses the olfactory epithelium and follows neural pathways to reach brain regions while avoiding systemic circulation.

PNALD can progress to irreversible liver injury despite needed nutrition; OCA activates FXR signaling to limit ROS and fibrosis.

Larazotide restores exocrine-gland tight junctions while anti-inflammatory compounds limit inflammation and lymphocyte infiltration.

Needle fear, device size, and aqueous degradation complicate epinephrine injections; dry powder nasal delivery enables rapid, precise dosing.

Low water solubility limits oral Apixaban absorption, while fatty acid or triglyceride addition and microfluidics support stable high-content encapsulation.

Afabicin combined with lipopeptides, glycopeptides, or lincosamides targets staphylococcal biofilms while reducing rifampicin resistance risk.

Modified phosphate groups give oligonucleotides neutral or positive charge, improving cell uptake and delivery without external agents.

Blocking double-membrane vesicle formation with VPS34 inhibitors can inhibit coronavirus replication, transmission, and protein expression.

Limited LXR agonist and antagonist efficacy is addressed with a 2′-isopropyl spiro oxindole regulator for metabolic disease and cancer.

Selective AC1 inhibition uses pyrazolyl pyrimidinone compounds to target chronic pain while limiting risks from broad adenylyl cyclase inhibition.

Culturing isolated T cells with hydroxycitric acid supports in vivo persistence and antitumor activity while reducing apoptosis.

Specific core substituents target A2a/A2b receptors to mitigate tumor immune suppression and enhance tumor-specific T-cell responses.

Cationic solution polymerization controls polyphosphazene molecular weight and polydispersity for biocompatible, hydrophilic drug carriers.

Deuterium-substituted azaindole compounds target ROCK1, ROCK2, and PRKX while addressing potency, bioavailability, and brain penetration limits.

Excessive IRF1 activation worsens radiation-induced skin injury; IRSKIN-1 inhibits its transcriptional activity to support tissue repair.

Tailored molecular structures preserve αvβ6 binding while enabling oral absorption as an alternative to injectable integrin inhibition.

Host-kinase phosphorylation can limit activation; sulfur-containing prodrugs redirect activation and delivery toward viral sanctuaries.

Reduced portal GLP-1r density impairs glucose sensing; local peri-portal delivery restores homeostasis while limiting systemic side effects.

See how FGFR inhibition addresses idiopathic short stature in children with normal growth hormone levels through bone elongation.

Limited light penetration restricts PDT for deep tumors; polyethylene imine particles enable ultrasound-activated sonosensitiser delivery with less invasive treatment.

Combining delayed-release naltrexone with lyophilized calcitriol separates gastrointestinal and oral-cavity absorption to improve delivery and reduce side effects.

Learn how nanoscale flubendazole particles and a non-ionic triblock copolymer prevent sedimentation, clogging, and dosing errors in medicated water.

Limited TRPA1 agonist options are addressed with mushroom extract or lenthionine to stimulate appetite and food intake.

Rapid ketamine elimination can shorten treatment and amplify adverse events; pamoate injections sustain release with fewer initial bursts.

Imatinib fails against KIT D816V mastocytosis; 2,3,5-substituted thiophene compounds inhibit cell growth, induce apoptosis, and reduce inflammation.

Ionic and hydrogen-bonded chitosan nanofibres shield bioactive compounds from gut degradation and carry controlled doses across the blood-brain barrier.

Enfumafungin derivatives inhibit β-D-glucan synthesis to reduce Pneumocystis cyst and trophic burdens through oral, well-tolerated therapy.

Specific miRNA-loaded extracellular vesicles from 3D stem-cell spheroids offer a non-surgical route to promote vascular anastomosis in Moyamoya disease.

Arimoclomol helps misfolded GBA achieve functional conformations, increasing enzyme levels and activity in mutation carriers.

Combining chemotherapy with non-steroidal SGRMs targets GR signaling in cervical cancer to improve tumor reduction while limiting healthy-tissue damage.

Arimoclomol induces HSP70 to address lysosomal dysfunction and neurological symptoms that standard Gaucher therapies may miss.

Glucose-dependent insulin secretion from novel bicyclic GPR40 agonists targets Type 2 diabetes with reduced hypoglycemia risk.

By targeting α2δ channels, the polycyclic derivative supports pain relief and antiepileptic effects with minimal adverse reactions.

GDP-fucose derivatives and fucosyltransferase attach therapeutic molecules to mature erythrocytes, reducing immune-cell therapy complexity.

CRY1 genotype testing guides tasimelteon treatment to phase-advance circadian timing and improve sleep in DSWPD.

Short dwell times and systemic absorption limit gemcitabine therapy; intravesical release sustains bladder exposure while reducing toxicity.

An aqueous-only priming sequence and multiport valve switch flow paths before mixing, reducing stock loss while preserving particle-size control.

Existing liver treatments lack effective ROR modulators; isoform-specific small molecules target RORα, RORβ, and RORγ for NASH.

Existing IDO/TDO inhibitors may lack specificity and efficacy; substituted spiro diones seek stronger, more selective suppression of both enzymes.

By targeting MAP4K4 as an intermediary, these selective compounds suppress cardiac muscle cell death and protect cardiomyocytes from injury.

Temporary gastrointestinal implants combined with metabolic and microbiota modulators address metabolic disorders while reducing reliance on additional interventions.

An ether-bonded PEG–hyaluronic acid polymer masks enzyme-sensitive glycosidic bonds, extending residence while retaining moisture.

An alcohol-free composition uses DMSO, epsilon poly L-lysine, and optional liposomes to preserve exosome structure during storage.

Pyridazine derivatives selectively inhibit NLRP3 to address chronic inflammation while preserving regulated immune defense.

Mannose-functionalized dendrimeric nanoparticles deliver therapeutic agents to plaque-associated macrophages.

Epinephrine nanoparticles enhance sublingual bioavailability through rapid mucosal absorption.

Phosphorothioate compounds neutralize radiation-induced free radicals to protect cellular DNA integrity.

Polymeric carriers improve therapeutic efficacy of the modulator to treat hepatic steatosis and antipsychotic-induced weight gain.

A fisetin and docosahexaenoic acid combination inhibits osteoclast differentiation while stimulating osteoblast activity.

Periodic MetAP2 inhibitor dosing reduces testes toxicity while maintaining weight loss efficacy.

Single-step nutrient germinant composition rapidly activates Bacillus spores in heated foods, eliminating multi-step process complexity.

Hydrolyzed activated PACE terpolymers resolve the contradiction between transfection efficiency and physiological stability to enable safe gene therapy.

A PCDH9 inhibitor targets leukemia cells to prevent central nervous system colonization in pediatric patients.

PROTAD compounds target and degrade the BCR-ABL fusion protein by recruiting E3 ubiquitin ligases, addressing chronic myeloid leukemia drug resistance.

Direct compression of Afatinib dimaleate eliminates roller compaction complexity while maintaining tablet hardness and dissolution profiles.

Allosteric inhibitors of cardiac myosin selectively modulate the cardiac sarcomere, resolving adverse effects like arrhythmias while improving contractility.

GABAA positive allosteric modulators address histamine-independent itch by targeting GABA receptors, bypassing ineffective antihistamines.

Antibody drug conjugates bind matriptase on malignant cells to deliver cytotoxic payloads directly to tumor sites.

Formula IIIA compounds modulate TGR5 receptors, improving metabolic profiles and energy expenditure while reducing cholic acid toxicity.

Substituted pyrimidines act as selective Toll-like receptor 8 agonists to modulate immune responses.

Crenolanib depletes peripheral blood and bone marrow blasts in FLT3 mutant AML patients, addressing limited remission durability.

Polymorphic forms of the EGFR inhibitor improve physical stability and solubility while maintaining activity against T790M and L858R mutants.

A combination of catechins and ornithine promotes ammonia metabolism through synergistic metabolic pathways.

Anti-adrenomedullin antibodies bind adrenomedullin to stabilize plasma levels, preventing edema and reducing mortality from fluid imbalance in sepsis.

Imidazoline derivatives inhibit androgen receptor activity in hormone-resistant prostate cancer by modifying chemical structures to maintain efficacy.

p62/SQSTM1 compositions modulate proinflammatory cytokines and osteogenic transcription factors, addressing side effects of existing anti-inflammatory drugs.

Pyrazolo[3,4-b]pyridine compounds inhibit TAM and MET kinases to reduce cancer metastasis.

A pyrazole-based compound suppresses inflammatory cytokines to reduce liver fat accumulation.

Gold(I) complexes with N-heterocyclic carbene and thiourea ligands induce apoptosis while minimizing serum albumin binding to reduce side effects.

Crystal forms K, G, E, and F of quinazolin crotyl dimaleate exhibit enhanced storage stability and water solubility compared to the free base.

Oral L-carnitine composition with antioxidants increases sperm count and motility, reducing reliance on invasive fertility techniques.

Triazole pyridyl compounds activate the APJ receptor to improve cardiac function while balancing potency and stability through structural optimization.

Formulation using green tea extract, partially hydrolyzed guar gum, and L-theanine suppresses intestinal microbial growth without antibiotic side effects.

Mixed acid salt polymer-drug conjugates resolve purity and yield trade-offs by stabilizing amine groups against hydrolytic degradation.

An IL-1 antagonist intercepts inflammatory signaling pathways, reducing neuronal damage without altering beta-amyloid plaque burden.

Segmented bicyclic pyridinone structures reduce amyloid beta plaques by precisely modulating gamma-secretase enzyme activity.

A chitosan film applied to the prostatic neurovascular bundle protects nerve fibers during surgery.

Pyrrolo-pyridine derivative inhibits DYRK1A to treat protein kinase-related diseases.

Sodium diacetate releases acetic acid to eradicate biofilm bacteria across a broad pH range, resolving the trade-off between efficacy and concentration limits.

Merges Toll-like receptor agonists with LAG-3 proteins to overcome insufficient single-adjuvant efficacy and sustain tumor rejection.

Angiotensin II restores renal perfusion and induces natriuresis in hepatorenal syndrome patients.

Androgen receptor downregulating agents overcome gemcitabine resistance in pancreatic ductal adenocarcinoma by disrupting oncogenic signaling pathways.

Bifunctional compounds link KAT6A to E3 ligases for targeted protein degradation, resolving selectivity limits of traditional inhibitors.

Selective 5-HT2C receptor modulation by Formula A compounds reduces food intake while maintaining a favorable safety profile.

Segmented dendritic polymer structures segregate detection and amplification steps to resolve signal-to-noise ratio trade-offs in complex mixtures.

High-energy mechanical grinding and controlled crystallization produce agomelatine form V with consistent dissolution properties.

Dimeric quinacrine derivatives overcome inconsistent hydroxychloroquine results by permeabilizing lysosome membranes to inhibit autophagy at lower doses.

Formula IIId amide compounds inhibit viral replication to combat drug-resistant HIV strains emerging from standard antiretroviral therapies.

Substituting trans-anethole with dihydroanethole prevents phenylephrine degradation caused by aldehyde formation, extending shelf life to 18 months.

Selective cholane derivatives modulate FXR and TGR5 receptors, preventing cholestatic pruritus and liver injury associated with direct agonism.

A shear-thinning hydrogel reduces viscosity under applied force to enable easy dispensing while maintaining high viscosity at rest.

Segmented THC and CBN components in a single tablet maintain sleep duration while preserving REM and deep sleep architecture.

Targeted gene inhibition suppresses excessive fibrous tissue growth during wound healing.

Bicistronic mRNA transfection enables simultaneous expression of patient-specific major histocompatibility complex and tumor antigens on antigen-presenting cells.

Selective norepinephrine inhibitors reduce cataplexy attacks and improve sleep quality without controlled substance restrictions.

Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives inhibit cathepsin A to modulate bradykinin levels and treat cardiovascular diseases.

CCN5 protein inhibits the TGF-β-SMAD pathway to prevent cardiac fibrosis and myocardial hypertrophy progression.

Downregulating TAP mediators induces novel antigen formation in infected cells to stimulate targeted immune responses.

Targeting untranslated regions reduces cytotoxicity while inhibiting MEX3B mRNA.

PKM2 modulators disrupt tumor metabolic balance and alter the microenvironment, resolving immune escape mechanisms in cancer treatment.

Probenecid inhibits renal excretion of aldose reductase inhibitors, extending their plasma half-life to reduce dosing frequency for diabetic complications.

In situ solid implant resolves plasma level homogeneity trade-offs through segmented burst and sustained release phases.

Spiropiperidine compounds resolve cardiotoxicology safety trade-offs while maintaining therapeutic efficacy for depression and obesity treatment.

Proteolysis targeting chimeras recruit E3 ligases to degrade Mcl-1, overcoming resistance and cardiotoxicity.

Milk exosomes deliver specific microRNAs to drive white adipocyte differentiation into thermogenic beige or brown cells.

[1,3]Diazino[5,4-d]pyrimidines bind covalently to the tyrosine kinase domain of mutant HER2 proteins.

A thermosensitive polymer coating on gold nanorods traps lipid-soluble anti-cancer drugs, preventing premature release during circulation.

CpG oligonucleotides induce endogenous cytokines to restore steroid efficacy in steroid-resistant inflammatory disease patients.

Synthesized via photosensitization, these compounds activate Akt-eNOS signaling to resolve ischemia reperfusion injury contradictions.

Xv1 inhibitor reduces X-box-binding protein 1 variant 1 levels to induce apoptosis and inhibit tumor growth.

Selective cardiac myosin potentiators resolve the trade-off between therapeutic effectiveness and adverse effects found in traditional inotropes.

Novel ortho-condensed 2-pyridinone derivatives act as nicotinic acid receptor agonists to treat metabolic syndrome and dyslipidemia.

Keratin-halofuginone hydrogels deliver controlled drug release to accelerate wound healing.

Purifying perfluoromethylcyclohexylpiperidine removes organic impurities that cause high reactogenicity in medical gas transmission emulsions.

Crosslinked hyaluronic acid amphiphilic polymers stabilize drug circulation and enable CD44-mediated tumor targeting.

Formula I compounds with specific substituents inhibit efflux pumps and detoxification enzymes to treat chemotherapy-resistant cancers.

Pteridinone derivatives inhibit non-classical mutant EGFRs, resolving poor efficacy against exon 18-21 insertions and ErbB2 mutations.

Crosslinked gelatin derivative nonwoven fabric delivers superior tissue adhesion and burst strength in wet surgical environments.

Trastuzumab-MCC-DM1 delivers cytotoxic maytansinoid DM1 to HER2-positive breast cancer cells through antibody-targeted delivery.

HEK293 cells expressing MrgprX2 receptors detect pseudo-allergic drug reactions via calcium mobilization, identifying adverse effects early in development.

Air-filled microshells in thin-film markers produce persistent color Doppler signals, eliminating X-ray radiation exposure during real-time surgical procedures.

Antibody-conjugated compounds target resistant cancer stem cells, enabling accurate detection and inhibition of tumor recurrence.

Composite adhesives resolve the trade-off between textile extensibility and water vapor impermeability in transdermal plasters.

SR-31747 resolves remdesivir efficacy uncertainty by blocking SARS-CoV-2 replication in animal models.

A thymoquinone and vitamin D composition reduces lipid droplet size in adipocytes.

Formulas I to XXV target inflammatory mediators and bacterial components to prevent sepsis risk in chemotherapy patients.

A pipette tip system featuring a conical rim and receiver opening that self-aligns to prevent static electricity buildup during handling.

High molecular weight hyaluronic acid reduces reactive oxygen species formation to protect eyes from blue light damage.

Tetrahydro-pyrazolo-pyridine compounds inhibit endosomal Toll-like receptors to reduce inflammatory cytokines in autoimmune diseases.

Gum base with low melting fat and minimal flavor increases salivary secretion by up to 30% while reducing thickness.

BGP15 rescues impaired mitochondrial function and reduces dorsal root ganglia neuron death, addressing IKAP deficiency causes rather than managing symptoms.

Oral Crm1 inhibitors modulate nuclear transport to treat tumors while minimizing central nervous system side effects from brain penetration.